A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
← catalyst calendarNCT07667803 · readout in 712 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
4,500estimated
Sites
321
Countries
Argentina, Australia, Brazil +16
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-29 | actual | When the study began enrolling |
| Primary completion | 2028-07-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-07-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Weight Management
Interventions
- Drug: Elecoglipron — also filed as Active IMP
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercent body weight loss
measured 72 weeks
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed